Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

First patients to receive new cancer drug in groundbreaking safety trial

NCT ID NCT07462377

Recruiting now Disease control Sponsor: EpiBiologics Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new drug called EPI-326. It aims to find a safe dose and see how the body handles the drug in patients with advanced lung cancer (with a specific genetic change) or advanced head and neck cancer. The main goal is to check for side effects, while also looking for early signs that the drug might help shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Astera Cancer Care

    NOT_YET_RECRUITING

    East Brunswick, New Jersey, 08816, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START Los Angeles

    NOT_YET_RECRUITING

    Los Angeles, California, 90025, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarah Cannon and HCA Research Institute

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • South Texas Accelerated Research Therapeutics (START)

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EGFR EPIDERMAL GROWTH FACTOR EPIDERMAL GROWTH FACTOR RECEPTOR EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION HEAD AND NECK HEAD AND NECK CANCER HEAD AND NECK CANCERS HEAD AND NECK SQUAMOUS CELL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC HNSCC NON SMALL CELL NON-SMALL CELL LUNG CANCER NON-SMALL-CELL LUNG NSCLC (NON-SMALL CELL LUNG CANCER)